Photoredox reactions using functionalized micelles and chromophores

Yoshikiyo Moroi; R. Humphrey-Baker; A. M. Braun; Michael Graetzel

doi:10.1016/j.ejso.2005.04.016

Article2003

Natural history and prognostic prediction of patients with hepatocellular carcinoma

Marı́a Varela, María Sala, Josep M. Llovet, Jordi Bruix

Alimentary Pharmacology & Therapeutics

Article1999

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Josep M. Llovet, Concepció Brú, Jordi Bruix

Seminars in Liver Disease

Article2014

Validation of Three Staging Systems for Hepatocellular Carcinoma (JIS Score, Biomarker-Combined JIS Score and BCLC System) in 4,649 Cases from a Japanese Nationwide Survey

Satoshi Kitai, Masatoshi Kudo, Namiki Izumi, Shuichi Kaneko, Yonson Ku, Norihiro Kokudo, Michiie Sakamoto, Tadatoshi Takayama, Osamu Nakashima, Masumi Kadoya, Yutaka Matsuyama, Takashi Matsunaga

Article2007

Clinical and molecular classification of hepatocellular carcinoma

Josep M. Llovet

Liver Transplantation

Article2017

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo, Masashi Hirooka, Yohei Koizumi, Yoichi Hiasa, Kazuto Tajiri, Hidenori Toyoda, Toshifumi Tada, Hironori Ochi, Koji Joko, Noritomo Shimada, Akihiro Deguchi, Toru Ishikawa, Michitaka Imai, Kunihiko Tsuji, Kojiro Michitaka

Photoredox reactions using functionalized micelles and chromophores

Abstract

Discussion(0)

Related publications

Natural history and prognostic prediction of patients with hepatocellular carcinoma

Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification

Validation of Three Staging Systems for Hepatocellular Carcinoma (JIS Score, Biomarker-Combined JIS Score and BCLC System) in 4,649 Cases from a Japanese Nationwide Survey

Clinical and molecular classification of hepatocellular carcinoma

Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis